Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Additional features of LC-mediated protection from UVR-induced keratinocyte apoptosis and skin injury.
  • Fig. S2. The role of accumulated monocytes and monocyte-derived DCs in UVR-induced skin injury.
  • Fig. S3. Additional features of LC-mediated protection of keratinocytes in vitro.
  • Fig. S4. Mice treated with EGFR inhibitor resemble Langerin-DTA mice and timing of epidermal EGFR activation after UVR exposure.
  • Fig. S5. Effect of human LCs on human keratinocytes without UVR and further characterization of in vitro LC-keratinocyte EGFR signaling.
  • Fig. S6. Characterization of mouse and human ADAM17 expression, LC-Ad17 mice, and Langerin-Cre mice.
  • Fig. S7. Effects of inducible ADAM17 deletion in LCs.
  • Fig. S8. Validation of EGFR ligand release assay and characterization of keratinocyte EGFR ligand release.
  • Fig. S9. Photosensitive MRL-Faslpr mice have more skin plasma cells and reduced LC EGFR ligand expression, LC ADAM17 activity, and LC EGFR ligand release.
  • Fig. S10. B6.Sle1yaa mice exhibit photosensitivity and characterization of EGFR ligand expression by their LCs.
  • Fig. S11. EGFR ligand application reduces the severity of UVR-induced skin lesions and lymph node B cell responses in SLE model mice.
  • Fig. S12. Model of protective LC-keratinocyte axis and dysfunction of this axis in lupus photosensitivity.
  • Fig. S13. Uncropped Western blot images.
  • Table S1. List of primary antibodies.
  • Table S2. Secondary antibodies and other staining reagents.
  • Reference (53)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S3 (Microsoft Excel format). Primary data.